Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density

Circulation

Volumn 99, Issue 15, 1999, Pages 1959-1964

  Zambon, Alberto ^a   Hokanson, John E ^a   Brown, B Greg ^b   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Lipids; Lipoproteins; Stenosis

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; ENZYME ACTIVITY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0033586641     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.1959     Document Type: Article

References (54)

1. Kannel WB, Gordon T, Castelli WP. Role of lipid and lipoprotein fractions in atherogenesis: the Framingham Study. Prog Lipid Res. 1981; 20:339-348.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
3. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994;90:1056-1069.
4. Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996;94: 2351-2354.
5. Hokanson JE, Austin MA, Brunzell JD. Measurement and clinical significance of low density lipoprotein subclasses. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997;14:267-282.
6. Crouse JR, Parks JS, Schey HM. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985;26:566-574.
7. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
8. Campos H, Genest JJ, Blijlevelns E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Shaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.
9. Coresh J, Kwiterovich PJ, Smith H, Bachorik P. Association of plasma triglyceride and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.
10. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Sheperd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106: 241-253.
11. Gardner CD, Fortmam SP, Krauss RM. Association of small, low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
12. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
13. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres J-P. Small, dense low-density lipoprotein particles as predictor of the risk of ischemic heart disease in men. Circulation. 1997;95: 69-75.
14. Austin MA, King M-C, Vranizan K, Krauss RM. The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
15. Watts GF, Mandalia S, Brunt JHN, Slavin BM, Coltart DJ, Lewis B. Independent association between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis regression study (STARS). Metabolism. 1993;42:1461-1467.
16. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 1996;94:2146-2153.
17. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclass in the Monitored Atherosclerosis Regression Study (MARS): treatment effect and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697-704.
18. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 1993;13:147-153.
19. Watson TDG, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb. 1994;14:902-910.
20. Tan CE, Foster L, Caslake MJ, Bedford D, Watson TDG, McConnell M, Packard CJ, Shepherd J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subtractions patterns in normolipidemic men and women. Arterioscler Thromb Vasc Biol. 1995;15: 1839-1848.
21. Lahdenpera S, Syvanne M, Kahri J, Taskinen M-R. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia. 1996;39: 453-461.
22. Brown G, Albers JJ, Fisher LD, Shaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
23. Marcovina SM, Albers JJ, Gamble B, Koschinsky ML, Gaur VP. The effect of the number of apolipoprotein (a) kringle 4 domains on the immunochemical measurement of lipoprotein (a). Clin Chem. 1995;41: 246-255.
24. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res. 1980;21: 284-291.
25. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. Large, buoyant, LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 1989;9: 319-325.
26. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. In: Segrest JP, Albers JJ, eds. Methods in Enzymology, Plasma Lipoproteins: Preparation, Structure, and Molecular Biology. Orlando, Fla: Academic Press; 1986:181-209.
27. Capell WH, Zambon A, Austin AA, Brunzell JD, Hokanson JE. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol. 1996;16:1040-1046.
28. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. New York, NY: John Wiley & Sons; 1972:181-274.
29. Iverius PH, Brunzell JD. Human adipose tissue lipoprotein lipase: changes with feeding in relation to postheparin plasma enzyme. Am J Physiol. 1985;249:326-334.
30. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterization of the heterozygote state of lipoprotein lipase deficiency. Arteriosclerosis. 1989;9:326-334.
31. Brown BG, Hillger LA, Lewis C, Zhao X-Q, Sacco D, Bisson B, Fisher L. A maximum confidence approach for measuring progression and regression of coronary artery disease in clinical trials. Circulation. 1993; 87(suppl 3):II-66-II-73.
32. Armitage P. Statistical Methods in Medical Research. Oxford, UK: Blackwell Scientific Publications; 1971:314.
33. Austin MA, King M-C, Vranizan K, Krauss RM. The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
34. Grundy SN. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation. 1997;95:1-4.
35. Bjornheden T, Babyi A, Bodjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996;123:43-56.
36. Anber V, Griffin BA, McConnel M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996;124:261-271.
37. de Graaf J, Hak-Lemmers H, Hectors M, Demacker P, Hendriks J, Stalenhof AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.
38. West of Scotland Coronary Prevention Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
39. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial (CARE). Circulation. 1998;97: 1446-1452.
40. Kinnunen PHJ, Virtanen JA, Vainio P. Lipoprotein lipase and hepatic endothelial lipase: their roles in plasma lipoprotein metabolism. Atheroscler Rev. 1983;11:65-105.
41. Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in men. Atherosclerosis. 1980;36:589-593.
42. Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest. 1994;94:2377-2384.
43. Guerra R, Wang J, Grundy SM, Cohen JC. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 1997;94:4532-4537.
44. Jansen H, Verhoeven AMJ, Weeks L, Kastelein JJP, Halley DDJ, van der Ouweland A, Jukema JW, Seidell JC, Birkenhager JC. Common C to T substitution at position -480 of the hepatic lipase promoter is associated with a lowered hepatic lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol. 1997;17:2837-2842.
45. 2 cholesterol. Arterioscler Thromb Vasc Biol. 1998;18:1723-1729.
46. Santamarina-Fojo S, Haudenchild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998; 9:211-220.
47. Brunzell JD, Deeb SS. Lipoprotein lipase, apo CII and hepatic lipase deficiency. In: Scriver CR , Beudet AL , Sly WS , Valle D, Vogelstein B, Childs B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill. In press.
48. Buchwald H, Matts J, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Ziniga WR, Hunter DW, Pearce MB, Bissen JK, Edmiston WA, Sawin HS, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
49. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
50. Shepherd J, Cobbe SM, Isles CG, Loriner AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
51. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
52. Sacks MF, Pfeffer MA, Moye LA, Rouleau JL, Rutheford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
53. Buchwald H, Vargo RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edminston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Kargnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Dissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
54. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial, II: the relationship of reduction in incidence of coronary artery disease to cholesterol lowering. JAMA. 1984;251:365-374.